Merck developing new one dose weekly diabetes drug

Merck is currently in Phase II clinical trials for their drug MK-3102.  This new diabetes fighting drug is unique because when taken once a week, it reduces HbA1c levels blood sugar levels. This was just based on trials with one drug. In Phase III, it will be tested in combination with other drugs to further reduce the blood sugar levels. There is currently only one other drug that can be taken twice a week according to Finance.com. It is not seen as a competitor as it's an injectable drug and targets a different market.

This February, Anders Boss, CSO, Mannkind Corporation will be looking more in-depth at the blood sugar drugs that are coming to the market in the presentation "Breakthroughs in Insulin Pharmacodynamics: The State of the Art and the Shape of the Future" at the first annual Innovation and Commercialization of Therapeutics for Metabolic Disorders.  For more information on this presentation and the rest of the program, download the agenda. If you'd like to join us, register today and mention code XP1803BLOG to save 15% off the standard rate.

Share this article with your social network, just click below to share now!

Share |